USFDA issues Form 483 with 6 observations to Sun Pharma's Mohali facility; Stock under pressure

16 Aug 2022 , 10:24 AM

Sun Pharmaceuticals Industries Limited has updated on US FDA Inspection at Mohali Facility.

As per the filing, the US FDA has conducted an inspection of Mohali manufacturing facility (Punjab, India) of Sun Pharmaceutical Industries from August 3, 2022 to August 12, 2022. At the conclusion of the inspection, the USFDA issued a Form-483, with 6 observations. 

The Company is preparing the response to the observations, which will be submitted to USFDA within the stipulated timeline., the  company said.

It further added, “The Company is committed to address these observations promptly. The Company remains committed to work closely with the US FDA and continues to enhance its compliance on an ongoing basis.”

At around 10:26 AM, Sun Pharmaceuticals Industries was currently trading at Rs910.95 per share down by Rs2.45 or 0.27% from its previous closing of Rs913.40 per share on the BSE.